Occupational and Environmental Causes of Autoimmune Diseases

NCT ID: NCT07000903

Last Updated: 2025-06-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

247 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-10

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesize that part of the systemic autoimmune diseases (AID) patients might prove to have an occupational or environmental disease which is potentially preventable. The recognition of the occupational or environmental etiology of autoimmune disorders has major implications for patients and society and will generate opportunity for prevention and meaningful clinical intervention. The investigators intend to use the urine/blood exposure measurements to demonstrate the etiological role of environment in patients developing AID patients.

The investigators are mounting an epidemiological study to elucidate the environmental etiology of AID and their effects on the immune profile and disease course. A population-based case-control study will be done with adult patients with newly diagnosed systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis (n=100 per disease).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Systemic autoimmune diseases (AID) regroup a broad range of related diseases characterized by self-damaging immune responses. They mainly comprise systemic lupus, systemic sclerosis and rheumatoid arthritis and remain a significant clinical challenge. Rheumatoid arthritis (RA) is a degenerative disease associated with chronic inflammation that ultimately leads to joint damage, deformation and destruction. Systemic lupus erythematosus (SLE) is characterized by tissue injury resulting from immune responses and serological changes. This multifaceted etiology AID is initiated by the loss of tolerance to self-antigens and the accumulation of autoreactive B and T cells that promote autoreactive antibody production, immune complex formation and activated mononuclear cell infiltration in affected tissues. Finally, small vessels-vasculopathology, internal tissue fibrogenesis and thickening skin characterize systematic sclerosis (SSc) patients. These lesions derive from dysregulated immune functions altering connective tissue integrity.

Several risk factors have been pinpointed to explain the triggering of these AID. Scientists have managed to identify the main genetic factors. Susceptibility to AID is strongly associated to MHC class II polymorphisms and adaptive immunity activation (particularly effector T lymphocytes).

Nevertheless, several studies have also emphasized the contribution of environmental factors, which may function as triggers of innate immunity and may contribute to the breakdown of self-tolerance by modifying protein antigens. Cigarette smoking has proven to be a strong risk factor for seropositive RA and SLE. Cigarette smoke leads to post-translational modifications of antigens by citrullination (citrullinated antigens) that induce the production of anticitrullinated protein antibodies (ACPA) and the onset of ACPA-positive RA. Occupational factors may also cause or trigger AID. In a retrospective study conjointly performed by the Cliniques Universitaires Saint-Luc (CUSL) and UZ Leuven, it was concluded that an estimated 50% of male patients suffering from SSc have occupational exposure to silica and solvents. These findings indicate that environmental factors can provide clinically useful information in the management of AID patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lupus Erythematosus, Systemic Systemic Sclerosis Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Verify the added value of environmental exposure and immunophenotyping to establish a possible etiology of AID: the exposure and immune profiles will be determined in HBM blood and urine samples collected prospectively during the first SOC visit.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exposure and immune profiles

The exposure and immune profiles will be determined in HBM blood and urine samples collected prospectively during the first SOC visit.

Group Type EXPERIMENTAL

Exposure and immune profiles

Intervention Type OTHER

The exposure and immune profiles will be determined in HBM blood and urine samples collected prospectively during the first SOC visit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exposure and immune profiles

The exposure and immune profiles will be determined in HBM blood and urine samples collected prospectively during the first SOC visit.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinically active lupus; systemic sclerosis; rheumatoid arthritis
* At least 18 years old
* Without first line disease-modifying therapy
* Written informed consent must be obtained before any assessment is performed

Exclusion Criteria

* Younger than 18
* Wearers of metal prostheses
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Université Catholique de Louvain

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

François Huaux, Pr

Role: STUDY_DIRECTOR

UCLouvain - IREC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cliniques universitaires Saint-Luc

Brussels, Brussels Capital, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021/21SEP/388

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Synergetic B-cell Immodulation in SLE
NCT02284984 COMPLETED PHASE2